Pharmacology/Pharmaceutical Industry
Phase 2 RCT: Adjunctive ketamine with relapse prevention–based psychological therapy shows promise for the treatment of alcohol use disorder.
12 Jan, 2022 | 08:42h | UTCAdjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder – The American Journal of Psychiatry (link to abstract – $ for full-text)
Commentary: People With AUD May Benefit From Combination of Ketamine, Mindfulness Therapy – Psychiatric News Alert
RCT: In premenopausal women with breast cancer, gonadotropin-releasing hormone analogs may preserve ovarian function against chemotherapy-induced gonadotoxic effects.
11 Jan, 2022 | 02:26h | UTCEffects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Randomized clinical trial finds administration of gonadotropin-releasing hormone analogs (GnRHa) with chemotherapy in premenopausal pts with #BreastCancer reduces risk of premature ovarian insufficiency (#POI) and promotes recovery of ovarian function. https://t.co/gymbKT9GWZ pic.twitter.com/OUOlIwPSsq
— JAMA Oncology (@JAMAOnc) December 30, 2021
Review | Newer generation antidepressants and withdrawal effects: reconsidering the role of antidepressants and helping patients to stop.
11 Jan, 2022 | 02:16h | UTC
Commentary from the author on Twitter (thread – click for more)
We were asked to write about balance of harms and benefits of antidepressants based on current knowledge for @DTB_BMJ, a BMJ journal that is famously independent and does not take pharma sponsorship/advertising https://t.co/QCg7Bo1F40 1/n
— Mark Horowitz (@markhoro) December 21, 2021
RCT: In children with sickle cell anemia, hydroxyurea in moderate doses (20 mg/kg per day) is not better than low doses (10 mg/kg per day) for primary stroke prevention.
11 Jan, 2022 | 02:10h | UTCHydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Haematology (link to abstract – $ for full-text)
Cohort Study: Ciprofloxacin exposure during pregnancy was not associated with miscarriage or major malformations in a nationwide study from Denmark.
11 Jan, 2022 | 02:08h | UTCCiprofloxacin exposure and adverse pregnancy outcomes: a Danish nationwide cohort study – BJOG (link to abstract – $ for full-text)
Cohort study: Among health care workers previously vaccinated with 2 doses of the Pfizer-BioNTech vaccine, receiving a third dose was associated with reduced risk of SARS-CoV-2 infection.
11 Jan, 2022 | 01:35h | UTCEditorial: Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection – JAMA
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19.
11 Jan, 2022 | 01:26h | UTC
Commentary on Twitter
Fantastic outpatient treatment approach from Ontario #COVID19 Clinical Practice Guidelines
Risk level:high mod low
Eg:high:Sotrovimab is recommended if NA Remdesivir if NA Fluvoxamine or Budesonide
Paxlovid/Molnupiravir not added coz not yet approved CA https://t.co/dDhj6vA0uv pic.twitter.com/4ucrKIcMn8— Antibiotic Stewa®️x? Bassam Ghanem (@ABsteward) January 8, 2022
CDC Report: COVID-19 vaccine safety in children aged 5–11 Years.
9 Jan, 2022 | 01:09h | UTCCommentary: COVID-19 vaccine appears safe in children aged 5–11 Years – News Medical
Commentary on Twitter
Early vaccine safety data for children ages 5–11 years old found that reactions such as fatigue and headaches were commonly reported following Pfizer-BioNTech #COVID19 vaccine. Everyone ages 5 years & older should get vaccinated as soon as possible. https://t.co/D66QgLRWni pic.twitter.com/8I48L5GmcG
— MMWR (@CDCMMWR) December 30, 2021
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
9 Jan, 2022 | 01:05h | UTCRisk of myocarditis following sequential COVID-19 vaccinations by age and sex – medRxiv
Note: this study is an updated analysis of a recent study published in Nature Medicine; see below:
Guideline: ADA 2022 Standards of Medical Care in Diabetes.
24 Dec, 2021 | 13:38h | UTCGuideline Homepage: ADA 2022 Standards of Medical Care in Diabetes – American Diabetes Association
Introduction: Standards of Medical Care in Diabetes—2022
Summary of Revisions: Standards of Medical Care in Diabetes—2022
Standards of Medical Care in Diabetes—2022 Guideline Abridged for Primary Care Providers
Video Summary: Standards of Care in Diabetes – 2022
- Improving Care and Promoting Health in Populations
- Classification and Diagnosis of Diabetes
- Prevention or Delay of Type 2 Diabetes and Associated Comorbidities
- Comprehensive Medical Evaluation and Assessment of Comorbidities
- Facilitating Behavior Change and Well-being to Improve Health Outcomes
- Glycemic Targets
- Diabetes Technology
- Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes
- Pharmacologic Approaches to Glycemic Treatment
- Cardiovascular Disease and Risk Management
- Chronic Kidney Disease and Risk Management
- Retinopathy, Neuropathy, and Foot Care
- Older Adults
- Children and Adolescents
- Management of Diabetes in Pregnancy
- Diabetes Care in the Hospital
- Diabetes Advocacy
Commentaries on Twitter
ADA's "Standards of Medical Care in Diabetes—2022" is finally here! Featuring American Diabetes Association's latest clinical practice recommendations, the global standard for diabetes care. #ADASOC2022
? READ NOW (OPEN ACCESS): https://t.co/LJZcW4Vrb8 pic.twitter.com/hMD2FZO0dj
— ADA Professional Publications (@ADA_Pubs) December 20, 2021
Now Online: SOC — 2022 Abridged ?
ADA’s Standards of Medical Care abridged to include recommendations most pertinent to primary care. Access is free online, with important updates noted throughout the year. #ADASOC2022
? READ NOW (OPEN ACCESS):https://t.co/gm6BaLT2s4 pic.twitter.com/qhwze7MMLo
— ADA Professional Publications (@ADA_Pubs) December 20, 2021
AAN Guideline: Oral and topical treatment of painful diabetic polyneuropathy.
8 Jan, 2022 | 23:18h | UTCNews Release: AAN Issues Guideline for Treatment of Painful Diabetic Neuropathy – American Academy of Neurology
AHA names top heart disease and stroke research advances of 2021.
8 Jan, 2022 | 23:14h | UTCAHA names top heart disease and stroke research advances of 2021 – American Heart Association
FDA approves first injectable treatment for HIV pre-exposure prevention.
8 Jan, 2022 | 23:04h | UTCCommentaries:
NIH celebrates FDA approval of long-acting injectable drug for HIV prevention – NIH News Releases
A new injection to prevent HIV, rather than pills, is a game-changer, scientists say – NPR
Related:
CDC Guidance: Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents
USPSTF Statement: Preexposure Prophylaxis for the Prevention of HIV Infection
British Guidelines on the Use of HIV Pre–exposure Prophylaxis (PrEP) (several guidelines on the subject)
New Protocol for HIV Prevention Drug Reduces The Number Of Pills Required
RCT: Long-term supplementation with marine Omega-3 fatty acids does not reduce the risk of depressive symptoms.
8 Jan, 2022 | 23:10h | UTCEffect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.
8 Jan, 2022 | 23:07h | UTCDolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Easy-to-take medicine better at suppressing HIV in children – University College London
Commentaries on Twitter
Dolutegravir-based antiretroviral therapy was compared with standard care in children and adolescents starting first- or second-line therapy for HIV type 1 infection. Dolutegravir-based ART was superior to standard-care ART. https://t.co/PP0XaEVswO pic.twitter.com/pQvhjdXcUk
— NEJM (@NEJM) December 29, 2021
Visual Abstract: Dolutegravir as First- or Second-Line HIV Treatment in Children https://t.co/2RIg9uH2V1 pic.twitter.com/mDr1Z6l6CJ
— NEJM (@NEJM) January 4, 2022
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.
8 Jan, 2022 | 22:45h | UTCJanus kinase-targeting therapies in rheumatology: a mechanisms-based approach – Nature Reviews Rheumatology (if the link is paywalled, try this one)
RCT: Vitamin D supplementation does not improve outcomes in people with early psychosis.
8 Jan, 2022 | 22:52h | UTC
M-A of two randomized trials: Among men with high-risk non-metastatic prostate cancer, adding abiraterone and prednisolone to standard androgen-deprivation therapy was associated with improved 6-year metastasis-free survival (82% vs. 69% in the control group).
8 Jan, 2022 | 22:42h | UTCAbiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol – The Lancet (link to abstract – $ for full-text)
Related Audio: Key messages of the recent report from the STAMPEDE trial platform
In a large retrospective cohort study of patients with atrial fibrillation 65 years or older, treatment with rivaroxaban compared with apixaban was associated with increased risk of major ischemic or hemorrhagic events.
8 Jan, 2022 | 22:37h | UTCCommentary: Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study – TCTMD
Related:
Retrospective cohort study: In patients with venous thromboembolism (VTE), treatment with apixaban was associated with lower rates for recurrent VTE and bleeding compared to rivaroxaban.
8 Jan, 2022 | 22:36h | UTCCommentaries:
Apixaban shows superior effectiveness, safety compared to rivaroxaban – ACP Internist
Recurrent VTE and Bleeding With Apixaban vs. Rivaroxaban – American College of Cardiology
RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes.
17 Dec, 2021 | 09:50h | UTCInvited commentary: Anticoagulation in COVID-19 – The Lancet
Commentary on Twitter
NEW: The role of extended thromboprophylaxis in patients hospitalised with COVID-19 at risk for thrombotic events after discharge – findings from MICHELLE trial https://t.co/OWcmjCLBTw pic.twitter.com/3Bl4lV16Va
— The Lancet (@TheLancet) December 16, 2021
RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.
17 Dec, 2021 | 09:52h | UTCRelated: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (several articles on the subject)
WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.
17 Dec, 2021 | 10:01h | UTCInterim recommendations for heterologous COVID-19 vaccine schedules – World Health Organization
Commentary: Coronavirus: WHO gives the nod for mix-and-match vaccine schedules – South China Morning Post
Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.
17 Dec, 2021 | 09:54h | UTCCommentaries:
Novavax COVID vaccine shows 90.4% efficacy against infection – CIDRAP
Novavax COVID-19 vaccine found to be safe and effective – University of Maryland School of Medicine
Related: [Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients. (several articles on the subject)
CDC advisors recommend mRNA COVID vaccines over J&J.
17 Dec, 2021 | 09:46h | UTCCDC advisors recommend mRNA COVID vaccines over J&J – CIDRAP